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Mitochondrial transplantation strategies as potential 
therapeutics for central nervous system trauma
Importance of Mitochondria in Health and 
Disease
Mitochondrial dysfunction is a hallmark of multiple 
central nervous system (CNS) diseases such as Alzhei-
mer’s disease, Parkinson’s disease, Alpers syndrome, 
Leigh syndrome, and myoclonic epilepsy with ragged 
red fibers, as well as following stroke and traumatic brain 
or spinal cord injury (Gollihue and Rabchevsky, 2017). 
Although various therapeutic agents have been used to 
target mitochondrial dysfunction, there are currently 
no clinically proven treatments that typically target one 
or few of the pathophysiological effects of mitochondria 
dysfunction and uncoupling, including reactive oxygen/
nitrogen species release and glutamate excitotoxicity. 
A novel treatment paradigm that targets mitochondrial 
dysfunction in injury and disease states is mitochondri-
al transfer and replacement strategies. There are many 
reported benefits to replacing mitochondria in injury or 
disease states, including increasing energy production, 
calcium buffering capacity, and replacing mitochondrial 
DNA. While mitochondrial transplantation from one 
source to recipient cells in vitro is performed by multiple 
labs, mitochondrial transplantation in vivo is burgeoning 
in models of acute lung injury and cardiac ischemia, and 
more recently in CNS models of stroke and Parkinson’s 
disease. The results show promise in sparing tissues, but 
such studies have used vastly different methodologies and 
discerning the optimal transplantation paradigms for cer-
tain animal models or outcome measures will continue to 
be challenging (for comprehensive review, see Gollihue 
and Rabchevsky, 2017).
Methods of Mitochondrial Transfer or 
Transplantation
Cell-mediated transfer of mitochondria is reported to 
be protective in models of acute lung injury and stroke. 
In these paradigms, a donor cell, whether implanted or 
endogenous, was found to secrete vesicles containing mi-
tochondria, which were subsequently taken into recipient 
cells. Mouse bone marrow derived stromal cells (mBMSC) 
have been instilled into lipopolysaccharide (LPS)-injured 
mouse lungs and shown to donate their mitochondria 
into the injured tissue, resulting in increased adenosine 
triphosphate (ATP) production and cell survival (Islam 
et al., 2012). The attachment of the mBMSC via connex-
in pore gap junction formation appeared necessary for 
this donation, with nanotubes formed between the cells 
and mitochondria-containing vesicles released (Figure 1 
nanotube). 
Others report that astrocytes release mitochondria-con-
taining vesicles in a mouse model of ischemic stroke (Ha-
yakawa et al., 2016). The mitochondria were then taken 
into and incorporated within neurons of the stroke in-
farct area within 24 hours after injury. Further, astrocytes 
could also be induced to release these mitochondria vesi-
cles in vitro, and after directly injecting them into mouse 
brains 3 days after stroke, the mitochondria were success-
fully incorporated into neurons (Figure 1 vesicle-medi-
ated). Notably, the CD38 protein was found necessary for 
the vesicle release from astrocytes. Remarkably, in both 
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the Hayakawa and Islam vesicle delivery systems, the re-
cipient cells were not the same cell type as the donor cell. 
Communication between the two cell types, however, 
appeared to be vital as Cx43 connexin pore formation or 
CD38 activation in donor cells were initiated by signals 
from the injured recipient cells. 
Successful mitochondrial transplantation in vivo, by 
directly injecting isolated autologous mitochondria into 
ischemic cardiac tissue before reperfusion (Masuzawa 
et al., 2013), results in improved mechanical function 
acutely, with benefits seen as soon as 10 minutes after 
injections. Importantly, confocal microscopy showed in-
corporation of exogenous mitochondria into cardiomyo-
cytes as quickly as 2 hours after transplantation, and due 
to such rapid uptake, the authors suggested an actin-de-
pendent internalization (Figure 1 microinjection). Di-
rect injections of autologous mitochondria in a porcine 
Figure 1 Exogenous mitochondria delivery techniques.
There are various techniques for transplanting exogenous mitochondria, including direct microinjection of isolated mitochondria, cell-mediated 
transfer utilizing tunneling nanotubes, vesicle-mediated delivery, and systemic delivery. Each of these results in mitochondria incorporation into 
host cells, where it is theorized the exogenous mitochondria may benefit the cell by providing new mitochondrial DNA, increasing calcium buffer-
ing capacity, and/or increased energy (ATP) production (Gollihue and Rabchevsky, 2017). 
model of cardiac ischemia showed similar beneficial 
results (Kaza et al., 2017), and there were no signs of in-
creased inflammatory or immune responses attributed 
to mitochondrial transplants. Exogenous mitochondria 
labeled with magnetic iron oxide particles were still ev-
ident using magnetic resonance imaging 4 weeks after 
transplant. 
Mitochondria isolated from transgenic cell lines with 
fluorescently labeled mitochondria have been directly 
microinjected into rat spinal cords and observed within a 
variety of host cell types after 24 and 48 hours (Gollihue 
et al., 2017), though mechanisms of uptake were not in-
vestigated. Alternatively, direct injections of isolated mi-
tochondria conjugated to Pep-1, a cell penetrating pep-
tide, into rat brains in a model of 6-hydroxydopamine (6-
OHDA) induced Parkinson’s disease have been visualized 
up to 12 weeks post injection (Chang et al., 2013; Chang 
196
Gollihue JL, Patel SP, Rabchevsky AG (2018) Mitochondrial transplantation strategies as potential therapeutics for central nervous system 
trauma. Neural Regen Res 13(2):194-197. doi:10.4103/1673-5374.226382
et al., 2016). It was posited that Pep-1 was essential for 
incorporation, unlike other reports of successful incorpo-
ration when directly injecting isolated mitochondria. 
Mitochondria have also been transplanted using sys-
temic delivery approaches (Figure 1 systemic). The same 
group that directly injected mitochondria into rabbit 
hearts also tested vascular perfusion of mitochondria in 
a rabbit model of focal cardiac ischemia (Cowan et al., 
2016). Mitochondria were isolated from human cardiac 
fibroblast cells and were perfused through the coronary 
artery after 30 minutes of cardiac ischemia. This study 
compared direct injection to systemic delivery tech-
niques and revealed that either delivery method resulted 
in functional protection of cardiac tissue. In a CNS-tar-
geted paradigm isolated mitochondria were delivered 
systemically via tail vein injections in a mouse model 
of Parkinson’s disease and found to increase behavioral 
recovery close to control levels (Shi et al., 2017). The 
fluorescent exogenous mitochondria were identified in 
multiple different organs and tissue types, including the 
brain, heart, liver, kidney, and muscle tissue. Systemic 
delivery showed that mitochondria reached both tar-
geted as well as untargeted tissues. Additionally, they 
posited that the uptake mechanism was endocytosis, as 
mitochondria were not incorporated into red blood cells, 
which lack endocytosis abilities. 
Mechanism of Incorporation
Various groups have shown successful mitochondria 
transplantation using various techniques that have simi-
lar results; mitochondrial incorporation into host tissues 
with beneficial outcomes (for comprehensive review see 
Gollihue and Rabchevsky, 2017). However, one question 
that few agree upon is not whether the mitochondria 
are incorporated, but rather how they are incorporated 
within the cell. While the very nature of mitochondrial 
compaction during the isolation protocols may con-
tribute to their facilitated intracellular delivery, various 
mechanisms have been tested in vitro, with the most de-
cisive stemming from studies showing actin-dependent 
mechanisms for incorporation of mitochondria (Pacak et 
al., 2015). However, it is not known whether the in vitro 
mechanisms of incorporation apply to in vivo models. 
Islam et al. (2012) showed that blocking endocytosis, 
using dynamin, inhibited mitochondrial transfer from 
mBMSC to injured lung epithelium. This led to the the-
ory that endocytosis was responsible for the uptake of 
mitochondria-containing vesicles (Figure 1 vesicle-me-
diated). They also reported that blocking the docking 
and formation of gap junction channels between the cells 
inhibited mitochondrial transfer, indicating communi-
cation between the injured cell and the donor cell was 
crucial. 
A possible incorporation mechanism in vivo for either 
mitochondrial organelles or vesicles could be a phenom-
enon known as massive endocytosis (Hilgemann et al., 
2013). This entails internalization of very large portions 
of the plasma membrane, and would allow for internal-
ization of things as large as whole organelles or vesicles. 
Once internalized, the mitochondria are released into 
the cytosol. 
Comparing Delivery Methods
While various transfer or transplantation methods 
showed successful incorporation into host tissues, each 
came with their own set of caveats. First, the integrity 
and/or health of the transplanted mitochondria was es-
tablished either by electron microscopy for morphology 
and purity (Cowan et al., 2016; Hayakawa et al., 2016; 
Gollihue et al., 2017; Kaza et al., 2017), measures of mi-
tochondrial respiration and energy production (Masuza-
wa et al., 2013; Cowan et al., 2016; Hayakawa et al., 2016; 
Gollihue et al., 2017; Kaza et al., 2017), maintenance of 
fluorescence membrane potential dyes (Hayakawa et 
al., 2016; Shi et al., 2017), and calcium buffering (Shi et 
al., 2017). Injection of mitochondria into tissues should 
be mindful of possible adverse effects due to various 
damage associated molecular patterns that could incite 
inflammatory or immune responses, although no signs 
of such overt reactions have been noted following direct 
injections (Masuzawa et al., 2013; Kaza et al., 2017). 
Isolated mitochondria themselves are at risk and vul-
nerable to possible adverse effectors in the extracellular 
environment including reactive oxygen and nitrogen 
species. Conjugating mitochondria to a carrier peptide 
allows for the transfer of the mitochondria across the 
plasma membrane, which could decrease the exposure 
time to the extracellular environment in addition to in-
creasing incorporation efficiency (Chang et al., 2016). 
Another approach would be to deliver mitochondria 
within either vesicles or liposomes (Figure 1), though 
a caveat to this technique is the difficulty in packaging 
high numbers of mitochondria within liposomes. Ves-
icles that are expelled from cells may contain other ele-
ments in addition to mitochondria, making it difficult to 
discern benefits afforded by mitochondrial transfer when 
other secretory molecules may play a part. 
Systemic delivery of mitochondria provides the added 
benefit of a more diverse incorporation profile, being 
taken into multiple organs and tissues, which could be 
beneficial depending upon the mitochondrial dysfunction 
phenotype. For instance, systemic delivery of mitochon-
dria after cardiac ischemia results in some exogenous 
mitochondrial colocalization within cardiomyocytes, 
but a larger amount of mitochondria were found in the 
interstitial spaces. If mitochondrial dysfunction is wide 
spread, such as in a genetic mitochondrial disorder, then 
this technique may have more effect. However, in injury 
or diseases in which mitochondria dysfunction is more 
focal, for instance around an injury site, then direct trans-
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plantation to concentrate healthy mitochondria within 
that injured tissue may be more applicable (Cowan et al., 
2016). 
There are also caveats to be considered concerning the 
source of donor mitochondria; whether to isolate from 
cell culture or attempt autologous transplants. Trans-
genic labeling of mitochondria in cell culture before 
transplantation can provide an indelible marker for visu-
alization in situ (Islam et al., 2012; Gollihue et al., 2017). 
However, only non-autologous mitochondrial trans-
plantation can be performed when using such a labeling 
paradigm. An additional benefit of using non-autologous 
transplant is that the exogenous mitochondrial DNA can 
be quantified in tissues using quantitative real-time PCR. 
While labeling isolated mitochondria before transplan-
tation with a MitoTracker dye or rhodamine derivative 
can be used for autologous transplants (Masuzawa et 
al., 2013), the fidelity of these markers to label only the 
transplanted mitochondria and not endogenous mito-
chondria is uncertain. 
Conclusions
As more studies utilize mitochondrial transplantation for 
therapeutics in various pathophysiological conditions, 
comparisons will lend to optimal techniques for both de-
livery and functional incorporation. Although there are 
still many questions as to the exact mechanisms by which 
mitochondria are both incorporated into cells and exert 
beneficial effects, transplantation strategies as therapeu-
tics for nervous system dysfunctions such as stroke, Par-
kinson’s disease and spinal cord injury are stimulating, 
though still in the experimental modeling stages. How-
ever, the McCully group is beginning to study clinical 
efficacy of mitochondrial transplant in pediatric cardiac 
dysfunction. Accordingly, depending upon the type of 
injury or disease model and the different tissues involved 
(i.e., cardiac vs. nervous vs. lung), the various delivery 
methods (Figure 1) can be refined for optimal effects. 
When precise mitochondrial incorporation mechanisms 
are elucidated, then delivery approaches can be targeted 
to specific tissues or cell types in future studies. Major 
advancements in the field of mitochondrial transplan-
tation will require unveiling the intricacies involved in 
successful transplantation and functional incorporation 
within cells. Consequent translation of these findings 
to the clinical setting may provide novel and impactful 
ways for mitochondrial transplantation to both protect 
and repair damaged tissues associate with CNS disease 
and trauma. 
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